Anthem Biosciences has successfully raised ₹1,016 crore from anchor investors, ahead of its upcoming Initial Public Offering (IPO) set to open for public subscription on July 14 and close on July 16. The Bengaluru-based biotech firm has garnered strong investor interest, with notable global and domestic institutional investors participating in the anchor allotment.
According to a circular posted on the BSE website, Anthem allocated 1.78 crore equity shares to 60 anchor funds at ₹570 per share, which is the upper end of the price band. The price band for the IPO has been set at ₹540 to ₹570 per share, and the total issue size stands at ₹3,395 crore.
Prominent investors in the anchor round include Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, PineBridge Global Funds, and Societe Generale. Leading domestic mutual funds such as HDFC MF, ICICI Prudential MF, Axis MF, UTI MF, Quant MF, and Motilal Oswal MF also participated.
The IPO is an Offer for Sale (OFS), meaning the company itself will not receive any proceeds from the issue. Instead, the funds raised will go to existing shareholders who are offloading their stake.
Anthem Biosciences is a Contract Research, Development and Manufacturing Organization (CRDMO), with a strong focus on innovation and technology. Its operations span the entire pharmaceutical value chain—from drug discovery to development and manufacturing. The company also produces a wide range of complex, fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
Anthem’s listed peers include Sai Life Sciences, Syngene International, Suven Life Sciences, and Divi's Laboratories—all notable players in the Indian pharma and life sciences ecosystem.
The book-running lead managers for the issue are JM Financial, Citigroup Global Markets India, J.P. Morgan India, and Nomura Financial Advisory and Securities (India).
The strong anchor book signals robust investor confidence in Anthem's business model and growth prospects as it prepares to enter the public markets.